Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease

Neurobiology of Disease

Volumn 54, Issue , 2013, Pages 339-348

  Fiorentini, Chiara ^a   Savoia, Paola ^a   Savoldi, Daria ^a   Barbon, Alessandro ^a   Missale, Cristina ^b  

^a National Institute of Neuroscience   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Caudate putamen; Dopamine D1 receptors; L DOPA induced dyskinesia; Parkinson's disease; Shp 2

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; BENSERAZIDE; DOPAMINE 1 RECEPTOR; LEVODOPA; MITOGEN ACTIVATED PROTEIN KINASE 1; OXIDOPAMINE; PROTEIN TYROSINE PHOSPHATASE SHP 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CORPUS STRIATUM; DISEASE SEVERITY; DYSKINESIA; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RAT;

ADRENERGIC AGENTS; ANIMALS; ANTIPARKINSON AGENTS; BLOTTING, WESTERN; DYSKINESIA, DRUG-INDUCED; IMMUNOPRECIPITATION; LEVODOPA; MALE; MAP KINASE SIGNALING SYSTEM; OXIDOPAMINE; PARKINSONIAN DISORDERS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D1;

EID: 84876307606     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.01.005     Document Type: Article

References (51)

1. Alcacer C.E., Santini E., Valjent F., Gaven J., Girault A., Herve D. Galpha(olf) mutation allows parsing the role of cAMP-dependent and extracellular signal-regulated kinase-dependent signaling in L-3,4-dihydroxyphenylalanine-induced dyskinesia. J. Neurosci. 2012, 32:5900-5910.
2. Andersson M., Hilbertson A., Cenci M.A. Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol. Dis. 1999, 6:461-474.
3. Aubert I., Guigoni C., Hakansson K., Li Q., Dovero S., Barthe N., et al. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann. Neurol. 2005, 57:17-26.
4. Ba M., Kong M., Yu G., Sun X., Liu Z., Wang X. GluR1 phosphorylation and persistent expression of levodopa-induced motor response alterations in the Hemi-Parkinsonian rat. Neurochem. Res. 2011, 36:1135-1144.
5. Barroso-Chinea P., Bezard E. Basal Ganglia circuits underlying the pathophysiology of levodopa-induced dyskinesia. Front. Neuroanat. 2010, 4:1-9. (art 131).
6. Buchwald P. Small-molecule protein-protein interaction inhibitors: therapeutic potential in light of molecular size, chemical space, and ligand binding efficiency considerations. IUBMB Life 2010, 62:724-731.
7. Calabresi P., Di Filippo M., Ghiglieri V., Tambasco N., Picconi B. Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. Lancet Neurol. 2010, 9:1106-1117.
8. Carta A.R., Tronci E., Pinna A., Morelli M. Different responsiveness of striatonigral and striatopallidal neurons to l-DOPA after a subchronic intermittent l-DOPA treatment. Eur. J. Neurosci. 2005, 21:1196-1204.
9. Cenci M.A., Lee C.S., Bjorklund A. l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 1998, 10:2694-2706.
10. Corvol J.C., Studler J.M., Schonn J.S., Girault J.A., Herve D. Galpha(olf) is necessary for coupling D1 and A2a receptors to adenylyl cyclase in the striatum. J. Neurochem. 2001, 76:1585-1588.
11. Corvol J.C., Muriel M.P., Valjent E., Feger J., Hanoun N., Girault J.A., et al. Persistent increase in olfactory type G-protein alpha subunit levels may underlie D1 receptor functional hypersensitivity in Parkinson disease. J. Neurosci. 2004, 24:7007-7014.
12. Darmopil S., Martin A.B., De Diego I.R., Ares S., Moratalla R. Genetic inactivation of dopamine D1 but not D2 receptors inhibits l-DOPA-induced dyskinesia and histone activation. Biol. Psychiatry 2009, 66:603-613.
13. Ding Y., Won L., Britt J.P., Lim S.A., McGehee D.S., Kang U.J. Enhanced striatal cholinergic neuronal activity mediates l-DOPA-induced dyskinesia in parkinsonian mice. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:840-845.
14. Dunnett S. l-DOPA, dyskinesia and striatal plasticity. Nat. Neurosci. 2003, 6:437-438.
15. Fiorentini C., Gardoni F., Spano P., Di Luca M., Missale C. Regulation of dopamine D1 receptor trafficking and desensitization by oligomerization with glutamate N-methyl-d-aspartate receptors. J. Biol. Chem. 2003, 278:20196-20202.
16. Fiorentini C., Rizzetti M.C., Busi C., Bontempi S., Collo G., Spano P., et al. Loss of synaptic D1 dopamine/N-methyl-d-aspartate glutamate receptor complexes in l-DOPA-induced dyskinesia in the rat. Mol. Pharmacol. 2006, 69:805-812.
17. Fiorentini C., Mattanza C., Collo G., Savoia P., Spano P., Missale C. The tyrosine phosphatase Shp-2 interacts with the dopamine D(1) receptor and triggers D(1)-mediated Erk signaling in striatal neurons. J. Neurochem. 2011, 117:253-263.
18. Gardoni F., Picconi B., Ghiglieri V., Polli F., Bagetta V., Bernardi G., et al. A critical interaction between NR2B and MAGUK in l-DOPA induced dyskinesia. J. Neurosci. 2006, 26:2914-2922.
19. Gerfen C.R., Miyachi S., Paletzki R., Brown P. D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. J. Neurosci. 2002, 22:5042-5054.
20. Ghiglieri V., Bagetta V., Pendolino V., Picconi B., Calabresi P. Corticostriatal Plastic Changes in Experimental l-DOPA-Induced Dyskinesia. Parkinson's Dis. 2012, (Electronic publication 2012 May 13) (ID358176). 10.1155/2012/358176.
21. Greengard P. The neurobiology of dopamine signaling. Biosci. Rep. 2001, 21:247-269.
22. Herve D., Levi-Strauss M., Marey-Semper I., Verney C., Tassin J.P., Glowinski J., et al. G(olf) and Gs in rat basal ganglia: possible involvement of G(olf) in the coupling of dopamine D1 receptor with adenylyl cyclase. J. Neurosci. 1993, 13:2237-2248.
23. Huang R., Martinez-Ferrando I., Cole P.A. Enhanced interrogation: emerging strategies for cell signaling inhibition. Nat. Struct. Mol. Biol. 2010, 17:646-649.
24. Lebel M., Chagniel L., Bureau G., Cyr M. Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat. Neurobiol. Dis. 2010, 38:59-67.
25. Lee F.J., Xue S., Pei L., Vukusic B., Chéry N., Wang Y., et al. Dual regulation of NMDA receptor functions by direct protein-protein interactions with the dopamine D1 receptor. Cell 2002, 111(2):219-230.
26. Lindgren H.S., Ohlin K.E., Cenci M.A. Differential involvement of D1 and D2 dopamine receptors in l-DOPA-induced angiogenic activity in a rat model of Parkinson's disease. Neuropsychopharmacology 2009, 34:2477-2488.
27. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., Cenci M.A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci. 2002, 15:120-132.
28. Mazzucchelli C., Vantaggiato C., Ciamei A., Fasano S., Pakhotin P., Krezel W., et al. Knockout of ERK1 MAP kinase enhances synaptic plasticity in the striatum and facilitates striatal-mediated learning and memory. Neuron 2002, 34:807-820.
29. Monville C., Torres E.M., Dunnett S.B. Validation of the l-DOPA-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists. Brain Res. Bull. 2005, 68:16-23.
30. Nadjar A., Gerfen C.R., Bezard E. Priming for l-DOPA-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease?. Prog. Neurobiol. 2009, 87:1-9.
31. Oh J.D., Del Dotto P., Chase T.N. Protein kinase A inhibitor attenuates levodopa-induced motor response alterations in the hemi-parkinsonian rat. Neurosci. Lett. 1997, 228:5-8.
32. Oh J.D., Chartisathian K., Ahmed S.M., Chase T.N. Cyclic AMP responsive element binding protein phosphorylation and persistent expression of levodopa-induced response alterations in unilateral nigrostriatal 6-OHDA lesioned rats. J. Neurosci. Res. 2003, 72:768-780.
33. Papa S.M., Engber T.M., Kask A.M., Chase T.N. Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res. 1994, 662:69-74.
34. Paul S., Snyder G.L., Yokakura H., Picciotto M.R., Nairn A.C., Lombroso P.J. The Dopamine/D1 receptor mediates the phosphorylation and inactivation of the protein tyrosine phosphatase STEP via a PKA-dependent pathway. J. Neurosci. 2000, 20:5630-5638.
35. Pavon N., Martin A.B., Mendialdua A., Moratalla R. ERK phosphorylation and FosB expression are associated with l-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol. Psychiatry 2006, 59:64-74.
36. Paxinos G., Watson C. The rat brain in stereotaxis coordinates 1986, Academic Press, San Diego, CA.
37. Picconi B., Centonze D., Hakansson K., Bernardi G., Greengard P., Fisone G., et al. Loss of bidirectional striatal synaptic plasticity in l-DOPA-induced dyskinesia. Nat. Neurosci. 2003, 6:501-506.
38. Poole A.W., Jones M.L. A SHPing tale: perspectives on the regulation of SHP-1 and SHP-2 tyrosine phosphatases by the C-terminal tail. Cell. Signal. 2005, 17:1323-1332.
39. Rangel-Barajas C., Silva I., Lopez-Santiago L.M., Aceves J., Erlij D., Floran B. l-DOPA-induced dyskinesia in hemiparkinsonian rats is associated with up-regulation of adenylyl cyclase type V/VI and increased GABA release in the substantia nigra reticulata. Neurobiol. Dis. 2011, 41:51-61.
40. Santini E., Valjent E., Usiello A., Carta M., Borgkvist J.A., Girault D., et al. Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in l-DOPA-induced dyskinesia. J. Neurosci. 2007, 27:6995-7005.
41. Santini E., Alcacer C., Cacciatore S., Heiman M., Herve D., Greengard P., et al. l-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice. J. Neurochem. 2009, 108:621-633.
42. Santini E., Sgambato-Faure V., Li Q., Savasta M., Dovero S., Fisone G., Bezard E. Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in l-DOPA-induced dyskinesia. PLoS One 2010, 5:e12322.
43. Santini E., Valjent E., Fisone G. mTORC1 signaling in Parkinson's disease and l-DOPA-induced dyskinesia: a sensitized matter. Cell Cycle 2010, 9:2713-2718.
44. Schallert T., Fleming S.M., Leasure J.L., Tillerson J.L., Bland S.T. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 2000, 39:777-787.
45. Schuster S., Nadjar A., Guo J.T., Li Q., Ittrich C., Hengerer B., et al. The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of l-DOPA-induced abnormal involuntary movements in experimental Parkinson's disease. J. Neurosci. 2008, 28:4311-4316.
46. Svenningsson P., Nishi A., Fisone G., Girault J.A., Nairn C., Greengard P. DARPP-32: an integrator of neurotransmission. Annu. Rev. Pharmacol. Toxicol. 2004, 44:269-296.
47. Thomas G.M., Huganir R.L. MAPK cascade signalling and synaptic plasticity. Nat. Rev. Neurosci. 2004, 5:173-183.
48. Valjent E., Corvol J.C., Pages C., Besson M.J., Maldonado R., Caboche J. Involvement of the extracellular signal-regulated kinase cascade for cocaine-rewarding properties. J. Neurosci. 2000, 20:8701-8709.
49. Valjent E., Pascoli V., Svenningsson P., Paul S., Enslen H., Corvol J.C., et al. Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:491-496.
50. Westin J.E., Vercammen L., Strome E.M., Konradi C., Cenci M.A. Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of l-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol. Psychiatry 2007, 62:800-810.
51. Zhuang X., Belluscio L., Hen R. G(olf)alpha mediates dopamine D1 receptor signaling. J. Neurosci. 2000, 20:RC91.